On Wednesday, Shares of Xerox Corp (NYSE:XRX), gained 0.19% to $10.72.
On Tuesday, December 29, 2015, Nasdaq Composite ended at 5,107.94, up 1.33%, Dow Jones Industrial Average advanced 1.10%, to finish the day at 17,720.98, and the S&P 500 closed at 2,078.36, up 1.06%.
Xerox Corp.’s stock raised by 1.13% to close Tuesday’s session at USD 10.70. The company’s shares fluctuated in the range of USD 10.63 and USD 10.77. A total of 4.69 million shares exchanged hands, which was lesser than its 50-day daily average volume of 12.02 million shares and its 52-week average volume of 10.54 million shares. Over the last three days Xerox Corp.’s shares have declined by 1.11%, while in the past one week the stock has moved up 3.88%. Furthermore, over the last three months the stock has gained 12.75% and in the past six months the shares have picked up 0.56%. The company has returned 13.49% in the past three months, on a compounded total return basis. Xerox Corp. has a current dividend yield of 2.57%. Further, the company is trading at a price to earnings ratio of 36.90 and a price to book ratio of 1.19. This compares to a historical PE ratio of 15.32 and historical PB ratio of 1.40.
Xerox Corporation provides business process and document administration solutions worldwide. The company’s Services segment offers various business process outsourcing services, such as customer care, transaction processing, human resources, communication and marketing, and consulting and analytics services, in addition to finance, accounting, and procurement services.
Shares of Cliffs Natural Resources Inc (NYSE:CLF), declined -2.91% to $1.67, during its last trading session.
Cliffs Natural Resources Inc. (CLF) has closed the sale of its remaining coal business, Pinnacle Mine in West Virginia and Oak Grove Mine in Alabama, to Seneca Coal Resources, LLC. Cliffs values the transaction at closing at $268 million based on Seneca Coal assuming all liabilities of the business. Additionally, Seneca Coal may pay Cliffs an earn out of up to $50 million contingent upon the terms of a revenue sharing plan which extends through the year 2020.
Lourenco Goncalves, Cliffs’ Chairman, President and Chief Executive Officer said, “The sale of Pinnacle and Oak Grove to Seneca Coal marks Cliffs’ exit from the coal business, and represents another very important step in the implementation of our US iron ore pellet-centric, environmentally compliant strategy. We are happy to have found a buyer that was able to agree on a transaction that not only brings real value to Cliffs shareholders, but will also preserve jobs for the exceptional people at these two mines.” Mr. Goncalves added: “I commend the Cliffs’ coal operations team for an outstanding job achieving great safety, production and quality results, preserving the value of our coal business in light of the many headwinds the industry has faced over this past year. This transaction was only made possible due to the high quality of our people at the coal mines, and I wish them the very best as they move forward with Seneca Coal.”
Cliffs said that the transaction closed upon signing of the deal on Dec. 22, 2015. The Company stated that the deal structure is a sale of the equity interests of Cliffs’ remaining coal business which comprises the legal entities of Cliffs North American Coal LLC; Pinnacle Mining Company, LLC; Pinnacle Land Company, LLC; Oak Grove Resources, LLC; Oak Grove Land Company, LLC; and Beard Pinnacle, LLC.
Cliffs Natural Resources Inc., a mining and natural resources company, produces iron ore and metallurgical coal. It operates five iron ore mines that produces iron ore pellets in Michigan and Minnesota; Koolyanobbing complex situated in northeast of the town of Southern Cross, which produces lump and fines iron ore; and two metallurgical coal mines located in Alabama and West Virginia.
Finally, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), ended its last trade with 3.26% gain, and closed at $10.76.
On Friday, December 18, 2015, the NASDAQ Composite ended at 4,923.08, down 1.59%, the Dow Jones Industrial Average declined 2.10%, to finish the day at 17,128.55, and the S&P 500 closed at 2,005.55, down 1.78%.
The stock of Achillion Pharmaceuticals Inc. gained 1.55% to close Friday’s session at USD 9.81. The shares of the company moved in the range of USD 9.47 and USD 9.99. A trading volume of 4.20 million shares was recorded, which was greater than its 150-day daily average volume of 2.85 million shares and its 52-week average volume of 3.78 million shares. Over the last five days Achillion Pharmaceuticals Inc.’s shares have advanced 6.40%, whereas in the past one month the stock has lost 1.70%. Additionally, over the last six months the shares have registered a profit of 11.60%. The company has returned 12.89% in the last three months, on a compounded total return basis. The stock is trading at a price to book (MRQ) ratio of 3.07, which compares to a historical PB ratio near to 8.85. Further, the stock is trading at a price to sales (TTM) ratio of 38.20.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
